Table 4 Effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^a.

From: Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

Sub-studies^b	Cases (PCR-positive)		Controls (PCR-negative)		Effectiveness in % (95% CI)^c
Sub-studies^b	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	Effectiveness in % (95% CI)^c
Effectiveness against symptomatic BA.1 Omicron infection^d
Dose 1
0–13 days after Dose 1 and no Dose 2	3	1942	8	3400	50.0 (−91.3 to 86.9)
≥14 days after Dose 1 and no Dose 2	14	1942	19	3405	−16.8 (−137.8 to 42.6)
Dose 2
1–3 months after Dose 2 and no Dose 3	6	1943	27	3396	71.0 (24.0 to 89.0)
4–6 months after Dose 2 and no Dose 3	289	1976	667	3377	31.3 (19.1 to 41.7)
≥7 months after Dose 2 and no Dose 3	1125	1999	1847	3638	−10.2 (−23.1 to 1.3)
Dose 3 (booster dose)
<1 month after Dose 3	55	1951	182	3377	51.5 (32.3 to 65.2)
≥1 month after Dose 3	36	1953	102	3396	45.3 (17.8 to 63.5)
Effectiveness against symptomatic BA.2 Omicron infection^e
Dose 1
0–13 days after Dose 1 and no Dose 2	8	5651	10	5649	20.0 (−102.7 to 68.4)
≥14 days after Dose 1 and no Dose 2	31	5645	27	5649	−15.4 (−95.1 to 31.8)
Dose 2
1–3 months after Dose 2 and no Dose 3	26	5664	40	5650	35.9 (−5.9 to 61.2)
4–6 months after Dose 2 and no Dose 3	989	5756	1059	5686	9.9 (−0.3 to 19.0)
≥7 months after Dose 2 and no Dose 3	2917	5627	2686	5858	−20.4 (−30.2 to −11.2)
Dose 3 (booster dose)
<1 month after Dose 3	164	5727	250	5641	39.4 (24.8 to 51.2)
≥1 month after Dose 3	92	5709	149	5652	41.9 (23.4 to 56.0)
Effectiveness against any symptomatic Omicron infection^f
Dose 1
0–13 days after Dose 1 and no Dose 2	17	11,987	11	7153	9.8 (−94.1 to 58.1)
≥14 days after Dose 1 and no Dose 2	52	11,984	36	7150	9.5 (−39.9 to 41.5)
Dose 2
1–3 months after Dose 2 and no Dose 3	47	12,014	51	7151	43.2 (15.0 to 62.1)
4–6 months after Dose 2 and no Dose 3	1863	12,321	1294	7205	18.7 (11.3 to 25.5)
≥7 months after Dose 2 and no Dose 3	5820	12,144	3112	7374	−13.7 (−21.3 to −6.6)
Dose 3 (booster dose)^g
1 week after Dose 3	100	11,912	73	7132	19.7 (−9.7 to 41.2)
2–3 weeks after Dose 3	151	12,038	182	7126	53.7 (41.5 to 63.3)
4–5 weeks after Dose 3	109	12,000	135	7131	53.7 (39.6 to 64.6)
≥6 weeks after Dose 3	124	11,963	113	7134	34.9 (14.6 to 50.4)

CI confidence interval, PCR polymerase chain reaction.
^aA symptomatic infection was defined as a PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.
^bIn each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.
^cVaccine effectiveness was estimated using the test-negative, case–control study design^11,12.
^dCases and controls were matched one-to-two by sex, 10-year-age group, nationality, and calendar week of PCR test.
^eCases and controls were matched one-to-one by sex, 10-year-age group, nationality, and calendar week of PCR test.
^fCases and controls were matched two-to-one by sex, 10-year-age group, nationality, and calendar week of PCR test.
^gTo assess booster effectiveness over longer time interval, the analysis for effectiveness against any symptomatic Omicron infection was subsequently extended until April 11, 2022. This extended analysis was done for only effectiveness against any symptomatic Omicron infection to optimize statistical precision with the larger case numbers.

Back to article page

Table 4 Effectiveness of the mRNA-1273 vaccine against symptomatic SARS-CoV-2 BA.1 Omicron infection, BA.2 Omicron infection, and any Omicron infection^a.

Search

Quick links